Cancer Research Aziza Shad Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujita, M.
Right arrow Articles by Nakamura, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujita, M.
Right arrow Articles by Nakamura, Y.
[Cancer Research 60, 6683-6687, December 1, 2000]
© 2000 American Association for Cancer Research

Regular Articles

Down-Regulation of Monocyte Chemotactic Protein-3 by Activated ß-Catenin

Manabu Fujita, Yoichi Furukawa, Yutaka Nagasawa, Michio Ogawa and Yusuke Nakamura1

Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639 [M. F., Y. F., Y. Nak.]; Department of Surgery II, Kumamoto University School of Medicine, Kumamoto 860-8556 [M. F., M. O.]; and Department of Medical Genetics, Biomedical Research Center, Osaka University Medical School, Osaka 565-0871 [Y. Nag.] Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Accumulation of intracellular ß-catenin, as a result of inactivation of the adenomatous polyposis coli (APC) gene or by mutation of the ß-catenin gene (CTNNB1) itself, is involved in a wide range of human cancers. By means of fluorescent differential display using a murine fibroblast cell line (L-MT), which expresses an activated form of ß-catenin that accumulates in the cells, we found that expression of murine monocyte chemotactic protein-3 (mMCP-3) was suppressed by activated ß-catenin. Inversely, expression of MCP-3 in human colon cancer cells was induced by depletion of ß-catenin after adenovirus-mediated transfer of wild-type APC genes into the cells. A reporter-gene assay indicated that the accumulation of ß-catenin in the nucleus suppressed activity of the MCP-3 promoter through a putative T-cell factor/lymphocyte enhancer factor (Tcf/LEF)-binding site, ATCAAAG; but when the promoter sequence contained a two-base substitution in the binding site, it failed to suppress reporter-gene (luciferase) activity. An electrophoretic mobility-shift assay using the putative Tcf/LEF-binding sequence revealed interaction of the candidate sequence with the ß-catenin complex. Furthermore, induction of MCP-3 cDNA into HT-29 colon cancer cells increased expression of two markers of differentiation: alkaline phosphatase and carcinoembryonic antigen. Our results implied that activation of ß-catenin through the Tcf/LEF signaling pathway may participate in colonic carcinogenesis by inhibiting MCP-3-induced differentiation of colorectal epithelial cells.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Recent progress in cancer research has underscored the importance of ß-catenin, a molecule that plays pivotal roles in cell-to-cell adhesion and in the Wnt/Wg signal-transduction pathway (1) . The Wnt/Wg pathway is critical for differentiation and morphogenesis in Drosophila and Xenopus (2) , and evidence of aberrant ventralization by ectopic expression of armadillo, the Drosophila homologue of ß-catenin, has implicated this protein in the determination of cell polarity (3) .

Accumulation of ß-catenin in the cytoplasm or nucleus as a consequence of mutant APC2 or ß-catenin (CTNNB1) genes is frequently observed in early stages of colorectal tumorigenesis (4 , 5) . Moreover deletions of, or mutations within, exon 3 of CTNNB1 have also been identified in tumors of liver, uterus, prostate, skin, and brain (6, 7, 8, 9, 10, 11) . Because wild-type APC promotes degradation of intracellular ß-catenin through phosphorylation of serine/threonine residues within exon 3, in which ß-catenin binds with glycogen synthase kinase 3ß (GSK-3ß) and Axin/Conductin, mutant forms of APC or ß-catenin impair the degradation process. Accumulated ß-catenin translocates into the nucleus, in which—in association with Tcf/LEF—it modulates transcription of target genes. Thus far, several transcriptional targets of the ß-catenin/Tcf/LEF complex have been identified, including c-myc, cyclin D1, matrilysin, c-Jun, fra-1, uPAR, ZO-1 (12, 13, 14, 15, 16) , and NBL-4 (17) . However, specific molecular targets that are associated with cell differentiation or cell polarity remain to be defined.

A number of chemokines belonging to the C-C subfamily have been identified in the past few years. One of them, MCP-3, is expressed and secreted by monocytes, fibroblasts, platelets, colonic epithelial cells, and some malignant tumor cells (18, 19, 20, 21, 22, 23) . MCP-3 activates monocytes, lymphocytes, dendritic cells, natural killer cells, and granulocytes (24) . Activation of dendritic cells and type I T cells by MCP-3 can reduce tumorigenicity (25) , but this mechanism is not well understood.

To clarify the role(s) of ß-catenin in human carcinogenesis, we aimed to identify genes regulated by its activated form (26) . We report here that the chemokine MCP-3 is down-regulated by activated ß-catenin through binding of the nuclear ß-catenin complex to a Tcf/LEF-binding sequence (12, 13) , which is present in the promoter region of MCP-3. We also describe evidence that down-regulation of MCP-3 may disturb differentiation of colonic cells. Our results bring to light a novel mechanism by which activated ß-catenin can participate in colorectal tumorigenesis.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines.
We had previously established a mouse fibroblast cell line, L-MT, by introducing into murine L cells a mutant ß-catenin transgene that lacked exon 3 (26) . COS-7 cells, human embryonic kidney 293 cell line, and human colon-cancer cell lines HT-29, SW480, SW948, and LoVo were obtained from the American Type Culture Collection (Rockville, MD). All of the cell lines were cultured as monolayers in appropriate media: L-MT, L, and HEK 293 cells in DMEM (Sigma Chemical Co., St. Louis, MO); SW480 and SW948 in Leibovitz’s L-15 and LoVo in Ham’s F12 (Life Technologies, Inc., Grand Island, NY); and HT-29 in RPMI 1640 (Sigma Chemical Co.). All of the media were supplemented with 10% fetal bovine serum (Cansera, Inc., Ontario, Canada) and 1% antibiotic/antimycotic solution (Sigma Chemical Co.), and all of the cells were grown at 37°C in an atmosphere of humidified air containing 5% CO2.

RNA Extraction and FDD.
Total RNA was extracted from L cells, L-MT cells and four human colon-cancer cell lines using TRIZOL Reagent (Life Technologies, Inc.) according to the manufacturer’s protocol. The FDD procedure was performed essentially as described previously (27) . PCR products were resuspended in formamide sequencing dye and electrophoresed for 3 h at 1800 V on sequencing gels containing 4% acrylamide (19:1) with 7 M urea. Gel images were analyzed with an FMBIO II Multi-View fluoroimager (TaKaRa, Tokyo, Japan). Bands that showed differential expression between L cells and L-MT cells were excised from the gels, and DNA was extracted by boiling the gel fragments in Tris-EDTA buffer. Each sample was reamplified for 30 cycles with the same primer set used for the FDD procedure. Reamplified products were cloned into pBluescript II SK (-) vector (Stratagene, La Jolla, CA) and sequenced using T3, T7 primers and an ABI PRISM Dye Terminator Cycle Sequencing FS Ready kit (Perkin-Elmer Applied Biosystems Division, Foster City, CA) according to the protocol provided by the supplier.

Immunocytochemistry.
Cultured cells, replated on chamber slides, were fixed with PBS containing 4% paraformaldehyde for 15 min and were then rendered permeable by incubation for 3 min at 4°C in PBS containing 0.1% Triton X-100. Cells were covered with 2% BSA in PBS for 30 min at room temperature to block nonspecific binding of antibody and then were incubated with a mouse anti-ß-catenin antibody (Transduction Laboratories, Lexington, KY). Antibodies were stained with a goat antimouse secondary antibody conjugated to rhodamine (Leinco Technologies, Inc., Ballwin, MO), and viewed with an ECLIPSE E800 microscope (Nikon, Tokyo, Japan).

Depletion of ß-Catenin by Adenovirus-mediated Gene Transfer.
Expression of the part of APC that corresponds to the 20-amino-acid repeats of its ß-catenin-binding domain is able to down-regulate ß-catenin (28) . Therefore, we constructed an adenoviral vector containing this domain (Ad-APC) by inserting a 2.5-kb HindIII fragment of APC cDNA into the HindIII site of the pAd-BgIII vector, which contains the cytomegalovirus promoter/enhancer and a bovine growth hormone polyadenylation signal flanked by Ad5 E1 sequences. The recombinant adenoviruses, constructed as described previously (29) , were propagated in the HEK293 cell line and purified by two rounds of CsCl density centrifugation. Viral titers were measured by a limiting-dilution bioassay using HEK293 cells. Cell monolayers were infected with the viral solutions and were incubated at 37°C for 1 h, with brief agitation every 15 min. Culture medium was added, and the infected cells were maintained at 37°C for 48 h. Overexpression of APC mRNA was detectable as early as 18 h after infection (data not shown).

Western Blotting.
Western blotting with mouse anti-ß-catenin (Transduction Laboratories) was performed as described elsewhere (30) .

Semiquantitative RT-PCR Analysis.
A 3-µg aliquot of total RNA from each cell line was reverse-transcribed for single-stranded cDNAs using oligo(dT)15 primer and Superscript II (Life Technologies, Inc., Rockville, MD). Each cDNA mixture was diluted for subsequent PCR amplification by monitoring GAPDH as a quantitative control. The PCR exponential phase was determined on 20–32 cycles to allow comparison among cDNAs developed from identical reactions. As an internal control, the amounts of cDNA were quantified and equalized by amplifying GAPDH. The primer sequences used for amplification were 5'-GACAACAGCCTCAAGATCATCA-3' and 5'-GGTCCACCACTGACACTGTG-3' for human GAPDH; 5'-CAACTACATGGTTTACATGTTC-3' and 5'-TGTTCCGAATGTCTGAGGAC-3' for mouse GAPDH; 5'-TCCAATTCTCATGTTGAAGCC-3' and 5'-GAGAAAGGACAGGGTATACAAA-3' for human MCP-3; and 5'-CACTCTCTTTCTCCACCATG-3' and 5'-GCTAACACAATGTTAAAGTGAC-3' for mouse MCP-3. All of the reactions involved initial denaturation at 94°C for 2 min followed by 20 cycles (for GAPDH) or by 32 cycles (for MCP-3) at 94°C for 30 s, 57°C for 30 s, and 72°C for 1 min, on a Gene Amp PCR system 9600 (Perkin-Elmer). The products were electrophoresed in 3% agarose gels and visualized by fragment Southern-blot analysis followed by the transfer to nylon membranes (Amersham, Cleveland, OH). The membranes were hybridized with 32P-labeled internal oligonucleotide probes. Each internal oligonucleotide sequence used for Southern-blot analysis as a probe was 5'-CCCAT GGCAAATTCCATGGC-3' for human GAPDH, 5'-CTCACGGCAAATTC AACGGC-3' for mouse GAPDH, 5'-GCTACAGAAGGACCACCAGTA-3' for human MCP-3, and 5'-TTCTGTTCAGGCACATTTCTTC-3' for mouse MCP-3.

Deletion Mutagenesis and Generation of MCP-3 Reporter Plasmids.
To generate a series of 5' deletion mutants of the human MCP-3 gene promoter, two fragments were cloned into appropriate enzyme sites of pGL3-Basic Vector (Promega, Madison, WI). Reporter assay was carried out using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI) according to the manufacturer’s protocol. A plasmid vector, pRL-TK (Promega), was cotransfected with each reporter construct into SW480, LoVo, and SW948 cells using FUGENE6 (Boehringer Mannheim, Mannheim, Germany) according to the supplier’s recommendations.

EMSA.
Preparation of nuclear extracts and EMSA were performed essentially as described previously (31) . Two pairs of double-stranded, 15-nucleotide DNAs were prepared by annealing two oligonucleotide DNAs: 5'-ACCAGAATCAAAGCC-3' and 5'-GGCTTTGATTCTGGT-3' for the wild-type DNA; and 5'-ACCAGAGCCAAAGCC-3' and 5'-GGCTTTGGCTCTGGT-3' for the mutant DNA. The wild-type DNA was end-labeled with polynucleotide kinase in the presence of [{gamma}-32P]ATP and served as a probe for EMSA. A typical binding reaction contained 10 µg of nuclear extract in 5 µl of extraction buffer [10 mM HEPES (pH 7.9), 400 mM NaCl, 1.5 mM MgCl2, 0.2 mM EGTA, and 20% glycerol], 0.1 ng of the radiolabeled probe, and 100 ng of deoxyinosine-deoxycytidine (dI·dC) in 25 µl of binding buffer (60 mM KCl, 1 mM EDTA, 1 mM DTT, and 10% glycerol). For the competition assays, 50 ng of wild-type or mutant unlabeled DNA was added in the reaction mixture. Samples were incubated for 20 min at room temperature, with or without 0.5 µg of anti-ß-catenin antibody and additional incubation for 20 min. Electrophoresis was performed at 4°C on 4% nondenaturing polyacrylamide (29:1) gels with 0.25x Tris-boric/EDTA buffer. The gels were dried and autoradiographed.

ELISA of CEA and Measurement of ALP Activity.
The entire coding region of human MCP-3 was cloned into an expression vector, pcDNA 3.1(+) (Invitrogen, Carlsbad, CA), under control of the cytomegalovirus promoter/enhancer. HT-29 colon-cancer cells expressing a high amount of MCP-3 transcript was selected in medium containing 1000 µg/ml geneticin and was subcloned (HT-29-MCP). As a control, HT-29 cells—transfected with the empty vector pcDNA 3.1(+)—were subcloned as well (HT-29-con). All of the cells were grown to 30–50% confluence, either with or without 2 mM sodium butyrate (NaB). After 72 h of incubation, cells were harvested and lysed with lysis buffer. The amount of CEA was analyzed by an ELISA using a commercially available kit (Enzymun-test CEA; Boehringer Mannheim). Measurement of ALP activity was performed as described elsewhere (32) .

Statistics.
The data were analyzed using an ANOVA and the Scheffé’s F test.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Identification of MCP-3 as a Gene Down-Regulated by Activated ß-Catenin.
We previously established a mouse fibroblast cell line, L-MT, in which a mutant form of ß-catenin observed in human cancer cells was introduced (26) . L-MT cells showed a multilayer growth pattern and displayed growth advantage in low-serum culture media compared with their parent cells, L cells. Expression of ß-catenin was up-regulated by the withdrawal of doxycycline in the L-MT cells. Using these cell lines, we aimed to isolate genes regulated by ß-catenin. FDD analysis using L-MT cells revealed a fragment (D15) the intensity of which was decreased in response to the accumulation of ß-catenin. DNA sequencing and a subsequent search of the databases for homologies revealed identity of the DNA sequence of D15 to sequences of murine MCP-3. The expression level of murine MCP-3 was inversely correlated with the increase of ß-catenin in L-MT cells on the withdrawal of doxycycline (Fig. 1A)Citation . That is, when we depleted the culture medium of doxycycline, a significant decrease of MCP-3 expression in L-MT cells was observed within 4 h, and expression became undetectable after 8 h (Fig. 1B)Citation . These results indicated that even a small amount of accumulated ß-catenin can reduce the expression of MCP-3.



View larger version (74K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. A, inverse correlation of expression levels of murine MCP-3 and ß-catenin. L cells and L-MT cells were grown without or with doxycycline at various concentrations for 48 h. RNAs and protein lysates from these cells were used for either semiquantitative RT-PCR [for mouse MCP-3 (mMCP-3) and mouse GAPDH (mGAPDH)] or Western blotting (for ß-catenin and ß-actin). B, time course of reduction of mMCP-3 in response to the accumulation of ß-catenin in L-MT cells. Prior to the deprivation of doxycycline, L-MT cells were incubated with medium containing 20 ng/ml doxycycline. RNAs and protein lysates, extracted from these cells at 0, 1, 2, 4, 8, and 12 h after the deprivation, were used for either semiquantitative RT-PCR (for mMCP-3 and mGAPDH) or Western blotting (for ß-catenin and ß-actin).

 
To confirm the inverse correlation between expression of MCP-3 and accumulation of ß-catenin, we used a viral vector designed to express the 20-amino-acid-repeat, ß-catenin-binding domain of APC (Ad-APC). Infection of these adenoviruses into colon-carcinoma cell line SW480, in which a large amount of ß-catenin accumulates in the nucleus and cytoplasm (33) , conferred an evident decrease of ß-catenin (Fig. 2A)Citation . However, this change was not observed when SW480 cells were infected with adenovirus containing the LacZ gene (Ad-LacZ; Fig. 2ACitation ). It was shown in our previous paper that the reduced expression of ß-catenin by Ad-APC was correlated with decreased Tcf/LEF-specific transactivation activity (34) . Transfection of the SW480 cells with Ad-APC significantly increased expression of human MCP-3, but no such change occurred in cells transfected with Ad-LacZ (Fig. 2B)Citation .



View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. A, depletion of nuclear and cytoplasmic ß-catenin after adenoviral transfer of APC into SW480 cells. Cells infected with Ad-APC or Ad-LacZ were fixed, incubated with anti-ß-catenin antibody, and then stained with a rhodamine-conjugated secondary antibody (x600). B, increased expression of MCP-3 in response to depletion of ß-catenin in SW480 cells.

 
Putative Tcf/LEF-binding Motif in the Promoter Region of Human MCP-3.
To identify an element responsible for transcription in the promoter region of hMCP-3, we constructed two reporter-plasmid clones containing different lengths of the region upstream of the luciferase gene (Fig. 3A)Citation . The luciferase activity of reporter-plasmid P1 was significantly lower than that of P2 in the three colon cancer cell lines examined (Fig. 3B)Citation , which indicated the presence of a transcription-suppressing element between -1586 and -924. Because this candidate region contained ATCAAAG, a possible Tcf/LEF-binding motif, we hypothesized that this motif might be responsible for the transcriptional repression. To investigate that hypothesis, we constructed reporter plasmid P1M, in which the candidate Tcf/LEF-binding motif was changed to GCCAAAG (Fig. 3A)Citation . The luciferase assay using these three plasmids revealed that the 1.6-kb fragment containing the mutated motif had lost the ability to suppress transcription of MCP-3; its luciferase activity was equivalent to that of the P2 fragment (Fig. 3B)Citation . These results implied that the putative Tcf/LEF-binding motif is involved in repression of MCP-3 transcription.



View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. A, construction of reporter-gene plasmids representing the MCP-3 was subcloned into a pGL3-Basic Vector (Promega, Madison, WI). Plasmid P1M, containing a two-base substitution in the putative Tcf/LEF-binding site. B, reporter assay of MCP-3 promoter using P1, P2, and P1M in three colon cancer cell lines was performed in triplicates. Error bar, SD. Significantly different from P1 at P < 0.01 (Scheffé’s F test).

 
To confirm a direct mode of interaction between the ß-catenin complex and this promoter element, we prepared a wild-type double-stranded DNA encompassing this sequence and a mutant DNA that involved replacing 2 bp within the motif. Using nuclear extracts from SW480 cells, we performed an EMSA experiment and found that the ß-catenin complex bound specifically to this putative element. The specific band was supershifted by the addition of anti-ß-catenin antibody (Fig. 4)Citation .



View larger version (62K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. EMSA using a 32P-labeled DNA probe containing the wild-type putative Tcf/LEF-binding element in the MCP-3 promoter and nuclear extracts of SW480 cells. The specific band corresponding to the DNA-ß-catenin Tcf/LEF complex was supershifted by the addition of anti ß-catenin antibody (Lane 2). An excess of unlabeled wild-type DNA or mutant DNA was used for competition experiments (Lanes 3 and 4).

 
Differentiation of Colon Cancer Cells by Overexpression of MCP-3.
To investigate the biological role of MCP-3 in the colon, we transfected hMCP-3 cDNA into colon cancer cell line HT-29, to establish HT-29-MCP3 in which a high level of MCP-3 was constitutively expressed. The HT-29-MCP3 cells showed no apparent difference from parental HT-29 cells in morphology, growth rate, or ability to form colonies (data not shown). However, we found significant differences in regard to CEA production and ALP activity between HT-29-MCP-3 cells and HT-29-con cells transfected with pcDNA 3.1(+) alone. Sodium butyrate (NaB) is known to promote differentiation of colonic epithelial cells (35, 36, 37, 38, 39, 40) , and NaB treatment of HT-29 cells increases both the CEA level and ALP activity significantly compared with untreated HT-29 cells. Even in the absence of NaB, HT-29-MCP3 cells revealed 1.7-fold and 1.3-fold excesses of CEA level and ALP activity respectively, compared with HT-29-con cells, whereas NaB treatment of HT-29-MCP3 cells further enhanced production of CEA (Fig. 5A)Citation and ALP (Fig. 5B)Citation activity.



View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. The effect of MCP-3 overexpression on differentiation. Production of CEA (A) and activity of ALP (B) were measured as markers of differentiation in cells transfected with vector alone (HT-29-con) or with the MCP-3 gene (HT-29-MCP3) with or without the addition of sodium butyrate (NaB), an agent that promotes differentiation. Error bar, SD. Significantly different from HT-29 control cells at P < 0.01 (Scheffé’s F test).

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The data presented here have demonstrated that MCP-3 is down-regulated by an activated form of ß-catenin, and that this decreased expression occurs through direct association of the ß-catenin complex with a putative Tcf/LEF-binding motif present in the MCP-3 promoter.

A number of other mammalian genes including c-myc, cyclin D1, matrilysin (matrix metalloproteinase-7), WISP, c-jun, fra-1, uPAR, ZO-1 (12, 13, 14, 15, 16 , 41 , 42) , and NBL4 (17) are known to be regulated by stabilization and activation of ß-catenin. Moreover, several target genes for Wnt signaling have been identified in Xenopus and Drosophila, among them, the nodal-related 3 gene Xnr3 (a member of the transforming growth factor ß superfamily); fibronectin; and homeobox genes engrailed, goosecoid, twin, siamois, and ultrabithorax (43, 44, 45, 46, 47, 48) . All of them except ZO-1 are transactivated by accumulation of ß-catenin. The down-regulation of Tcf-dependent transcription by Groucho, CREB-binding protein (CBP), Sox protein, and NF-{kappa}B essential modulator-like kinase (NLK) were also reported, although their association with accumulation of ß-catenin is unclear at present (49, 50, 51, 52, 53) . Down-regulation of genes by Tcf/LEF is thought to reflect one of the following possibilities: (a) Tcf/LEF may bind directly to its binding motif and suppress transcription; (b) because WRM, the homologue of ß-catenin in Caenorhabditis elegans, is required to down-regulate the Tcf-like protein POP-1 (54) , reduced expression may result from repression of another Tcf-family protein that recognizes a similar binding motif; or (c) the suppression may be a secondary effect of primary targets of Tcf/LEF. These possibilities have not been resolved as yet. However, our data regarding the MCP-3 gene clearly demonstrate that decreased expression by the ß-catenin complex is one mechanism by which ß-catenin regulates downstream genes. Because the Tcf/LEF complex recruits various coactivators or corepressors to modulate transcription, it is conceivable that these associated molecules in combination may determine the function of the complex.

In HT-29 cells, we also found that overexpression of MCP-3 induces CEA and ALP activities, both of which are known to be differentiation markers for the cells (32 , 35, 36, 37, 38, 39, 40) . We did not detect any morphological differences between MCP-3-transfected HT-29 cells and their parent cells, which may suggest that the effect of MCP-3 alone is not enough to induce detectable morphological changes or that it is involved in a differentiation process not related to microscopic appearance. Hence, repression of MCP-3 may suppress differentiation of the colonic epithelium; this would represent a heretofore-unsuspected mechanism operating in colorectal tumor cells; i.e., inhibition of differentiation by activated ß-catenin. Although the relationship between MCPs and differentiation in colonic cells has not been investigated thoroughly, one group (55) has found that expression of MCP-1 in parenchymal cells was correlated with the histological grade of invasive ductal breast carcinomas. In addition, impaired expression of MCP-1 was involved in cervical tumorigenesis (56) . Therefore, the novel role of ß-catenin revealed in the experiments documented here has brought a more profound understanding of the mechanisms that underlie colorectal tumorigenesis. Furthermore, controlling MCP-3 expression may represent a means of therapeutic intervention for the treatment of cancer patients in the future.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Phone: 81-3-5449-5372; Fax: 81-3-5449-5433; E-mail: yusuke{at}ims.u-tokyo.ac.jp Back

2 The abbreviations used are: APC, adenomatous polyposis coli; Tcf, T-cell factor; Tcf/LEF, Tcf/lymphocyte enhancer factor; MCP, monocyte chemotactic protein; FDD, fluorescent differential display; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CEA, carcinoembryonic antigen; ALP, alkaline phosphatase. Back

Received 12/28/99. Accepted 10/ 3/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bullions L. C., Levine A. J. The role of ß-catenin in cell adhesion, signal transduction, and cancer. Curr. Opin. Oncol., 10: 81-87, 1998.[Medline]
  2. Siegfried E., Perrimon N. Drosophila wingless: a paradigm for the function and mechanism of Wnt signaling. BioEssays, 16: 395-404, 1994.[Medline]
  3. Cox R. T., Kirkpatrick C., Peifer M. Armadillo is required for adherens junction assembly, cell polarity, and morphogenesis during Drosophila embryogenesis. J. Cell Biol., 134: 133-148, 1996.[Abstract/Free Full Text]
  4. Iwao K., Nakamori S., Kameyama M., Imaoka S., Kinoshita M., Fukui T., Ishiguro S., Nakamura Y., Miyoshi Y. Activation of the ß-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res., 58: 1021-1026, 1998.[Abstract/Free Full Text]
  5. Sparks A. B., Morin P. J., Vogelstein B., Kinzler K. W. Mutational analysis of the APC/ß-catenin/Tcf pathway in colorectal cancer. Cancer Res., 58: 1130-1134, 1998.[Abstract/Free Full Text]
  6. Miyoshi Y., Iwao K., Nagasawa Y., Aihara T., Sasaki Y., Imaoka S., Murata M., Shimano T., Nakamura Y. Activation of the ß-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res., 58: 2524-2527, 1998.[Abstract/Free Full Text]
  7. Kobayashi K., Sagae S., Nishioka Y., Tokino T., Kudo R. Mutations of the ß-catenin gene in endometrial carcinomas. Jpn. J. Cancer Res., 90: 55-59, 1999.[Medline]
  8. Voeller H. J., Truica C. I., Gelmann E. P. ß-Catenin mutations in human prostate cancer. Cancer Res., 58: 2520-2523, 1998.[Abstract/Free Full Text]
  9. Rimm D. L., Caca K., Hu G., Harrison F. B., Fearon E. R. Frequent nuclear/cytoplasmic localization of ß-catenin without exon 3 mutations in malignant melanoma. Am. J. Pathol., 154: 325-329, 1999.[Abstract/Free Full Text]
  10. Zurawel R. H., Chiappa S. A., Allen C., Raffel C. Sporadic medulloblastomas contain oncogenic ß-catenin mutations. Cancer Res., 58: 896-899, 1998.[Abstract/Free Full Text]
  11. Chan E. F., Gat U., McNiff J. M., Fuchs E. A common human skin tumor is caused by activating mutations in ß-catenin. Nat. Genet., 21: 410-413, 1999.[Medline]
  12. He T. C., Sparks A. B., Rago C., Hermeking H., Zawel L., da Costa L. T., Morin P. J., Vogelstein B., Kinzler K. W. Identification of c-MYC as a target of the APC pathway. Science (Washington DC), 281: 1509-1512, 1998.[Abstract/Free Full Text]
  13. Korinek V., Barker N., Morin P. J., van Wichen D., de Weger R., Kinzler K. W., Vogelstein B., Clevers H. Constitutive transcriptional activation by a ß-catenin-Tcf complex in APC-/- colon carcinoma. Science (Washington DC), 275: 1784-1787, 1997.[Abstract/Free Full Text]
  14. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D’Amico M., Pestell R., Ben-Ze’ev A. The cyclin D1 gene is a target of the ß-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA, 96: 5522-5527, 1999.[Abstract/Free Full Text]
  15. Crawford H. C., Fingleton B. M., Rudolph-Owen L. A., Goss K. J., Rubinfeld B., Polakis P., Matrisian L. M. The metalloproteinase matrilysin is a target of ß-catenin transactivation in intestinal tumors. Oncogene, 18: 2883-2891, 1999.[Medline]
  16. Mann B., Gelos M., Siedow A., Hanski M. L., Gratchev A., Ilyas M., Bodmer W. F., Moyer M. P., Riecken E. O., Buhr H. J., Hanski C. Target genes of ß-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. USA, 96: 1603-1608, 1999.[Abstract/Free Full Text]
  17. Ishiguro H., Furukawa Y., Daigo Y., Miyoshi Y., Nagasawa Y., Nishiwaki T., Kawasoe T., Fujita M., Satoh S., Miwa N., Fujii Y., Nakamura Y. Isolation and characterization of human NBL4, a gene involved in the ß-catenin/Tcf signaling pathway. Jpn. J. Cancer Res., 91: 597-603, 2000.[Medline]
  18. Uguccioni M., D’Apuzzo M., Loetscher M., Dewald B., Baggiolini M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 {alpha} and MIP-1 ß on human monocytes. Eur. J. Immunol., 25: 64-68, 1995.[Medline]
  19. Menten P., Proost P., Struyf S., Van Coillie E., Put W., Lenaerts J. P., Conings R., Jaspar J. M., De Groote D., Billiau A., Opdenakker G., Van Damme J. Differential induction of monocyte chemotactic protein-3 in mononuclear leukocytes and fibroblasts by interferon-{alpha}/ß and interferon-{gamma} reveals MCP-3 heterogeneity. Eur. J. Immunol., 29: 678-685, 1999.[Medline]
  20. Power C. A., Clemetson J. M., Clemetson K. J., Wells T. N. Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine, 7: 479-482, 1995.[Medline]
  21. Uguccioni M., Gionchetti P., Robbiani D. F., Rizzello F., Peruzzo S., Campieri M., Baggiolini M. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am. J. Pathol., 155: 331-336, 1999.[Abstract/Free Full Text]
  22. Van Damme J., Proost P., Lenaerts J. P., Opdenakker G. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J. Exp. Med., 176: 59-65, 1992.[Abstract/Free Full Text]
  23. Van Snick J., Houssiau F., Proost P., Van Damme J., Renauld J. C. I-309/T cell activation gene-3 chemokine protects murine T cell lymphomas against dexamethasone-induced apoptosis. J. Immunol., 157: 2570-2576, 1996.[Abstract]
  24. Proost P., Wuyts A., Van Damme J. Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J. Leukocyte Biol., 59: 67-74, 1996.[Abstract]
  25. Fioretti F., Fradelizi D., Stoppacciaro A., Ramponi S., Ruco L., Minty A., Sozzani S., Garlanda C., Vecchi A., Mantovani A. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J. Immunol., 161: 342-346, 1998.[Abstract/Free Full Text]
  26. Nagasawa Y., Miyoshi Y., Iwao K., Shinomura Y., Matsuzawa Y., Nakamura Y. Transformation and morphological changes of murine L cells by transfection with a mutated form of ß-catenin. Cancer Res., 59: 3539-3542, 1999.[Abstract/Free Full Text]
  27. Yoshikawa Y., Mukai H., Asada K., Hino F., Kato I. Differential display with carboxy-X-rhodamine-labeled primers and the selection of differentially amplified cDNA fragments without cloning. Anal. Biochem., 256: 82-91, 1998.[Medline]
  28. Takahashi M., Ilan Y., Chowdhury N. R., Guida J., Horwitz M., Chowdhury J. R. Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period. J. Biol. Chem., 271: 26536-26542, 1996.[Abstract/Free Full Text]
  29. McGrory W. J., Bautista D. S., Graham F. L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology, 163: 614-617, 1988.[Medline]
  30. Daigo Y., Nishiwaki T., Kawasoe T., Tamari M., Tsuchiya E., Nakamura Y. Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21. 3. Cancer Res., 59: 1966-1972, 1999.[Abstract/Free Full Text]
  31. van de Wetering M., Oosterwegel M., Dooijes D., Clevers H. Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box. EMBO J., 10: 123-132, 1991.[Medline]
  32. Buras R. R., Shabahang M., Davoodi F., Schumaker L. M., Cullen K. J., Byers S., Nauta R. J., Evans S. R. The effect of extracellular calcium on colonocytes: evidence for differential responsiveness based upon degree of cell differentiation. Cell Proliferation, 28: 245-262, 1995.[Medline]
  33. Munemitsu S., Albert I., Souza B., Rubinfeld B., Polakis P. Regulation of intracellular ß-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc. Natl. Acad. Sci. USA, 92: 3046-3050, 1995.[Abstract/Free Full Text]
  34. Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T., Kawasoe T., Ishiguro H., Fujita M., Tokino T., Sasaki Y., Imaoka S., Murata M., Simano T., Nakamura Y. AXIN1 mutations in hepatocellular carcinomas and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet., 24: 245-250, 2000.[Medline]
  35. Tanaka Y., Bush K. K., Eguchi T., Ikekawa N., Taguchi T., Kobayashi Y., Higgins P. J. Effects of 1,25-dihydroxyvitamin D3 and its analogs on butyrate-induced differentiation of HT-29 human colonic carcinoma cells and on the reversal of the differentiated phenotype. Arch. Biochem. Biophys., 276: 415-423, 1990.[Medline]
  36. Herz F., Schermer A., Halwer M., Bogart L. H. Alkaline phosphatase in HT-29, a human colon cancer cell line: influence of sodium butyrate and hyperosmolality. Arch. Biochem. Biophys., 210: 581-591, 1981.[Medline]
  37. Morita A., Tsao D., Kim Y. S. Effect of sodium butyrate on alkaline phosphatase in HRT-18, a human rectal cancer cell line. Cancer Res., 42: 4540-4545, 1982.[Abstract/Free Full Text]
  38. Barnard J. A., Warwick G. Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells. Cell Growth Differ., 4: 495-501, 1993.[Abstract]
  39. Wiltz O., O’Hara C. J., Steele G. D., Jr., Mercurio A. M. Expression of enzymatically active sucrase-isomaltase is a ubiquitous property of colon adenocarcinomas. Gastroenterology, 100: 1266-1278, 1991.[Medline]
  40. Fantini J., Rognoni J. B., Culouscou J. M., Pommier G., Marvaldi J., Tirard A. Induction of polarized apical expression and vectorial release of carcinoembryonic antigen (CEA) during the process of differentiation of HT29–D4 cells. J. Cell. Physiol., 141: 126-134, 1989.[Medline]
  41. Brabletz T., Jung A., Dag S., Hlubek F., Kirchner T. ß-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol., 155: 1033-1038, 1999.[Abstract/Free Full Text]
  42. Pennica D., Swanson T. A., Welsh J. W., Roy M. A., Lawrence D. A., Lee J., Brush J., Taneyhill L. A., Deuel B., Lew M., Watanabe C., Cohen R. L., Melhem M. F., Finley G. G., Quirke P., Goddard A. D., Hillan K. J., Gurney A. L., Botstein D., Levine A. J. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc. Natl. Acad. Sci. USA, 95: 14717-14722, 1998.[Abstract/Free Full Text]
  43. Marikawa Y., Elinson R. P. Relationship of vegetal cortical dorsal factors in the Xenopus egg with the Wnt/ß-catenin signaling pathway. Mech. Dev., 89: 93-102, 1999.[Medline]
  44. Gradl D., Kuhl M., Wedlich D. The Wnt/Wg signal transducer ß-catenin controls fibronectin expression. Mol. Cell. Biol., 19: 5576-5587, 1999.[Abstract/Free Full Text]
  45. Eisenmann D. M., Maloof J. N., Simske J. S., Kenyon C., Kim S. K. The ß-catenin homolog BAR-1 and LET-60 Ras coordinately regulate the Hox gene lin-39 during Caenorhabditis elegans vulval development. Development (Camb.), 125: 3667-3680, 1998.[Abstract]
  46. McGrew L. L., Takemaru K., Bates R., Moon R. T. Direct regulation of the Xenopus engrailed-2 promoter by the Wnt signaling pathway, and a molecular screen for Wnt-responsive genes, confirm a role for Wnt signaling during neural patterning in Xenopus. Mech. Dev., 87: 21-32, 1999.[Medline]
  47. Nelson R. W., Gumbiner B. M. ß-Catenin directly induces expression of the Siamois gene, and can initiate signaling indirectly via a membrane-tethered form. Ann. NY Acad. Sci., 857: 86-98, 1998.[Medline]
  48. van de Wetering M., Cavallo R., Dooijes D., van Beest M., van Es J., Loureiro J., Ypma A., Hursh D., Jones T., Bejsovec A., Peifer M., Mortin M., Clevers H. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell, 88: 789-799, 1997.[Medline]
  49. Cavallo R. A., Cox R. T., Moline M. M., Roose J., Polevoy G. A., Clevers H., Peifer M., Bejsovec A. Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature (Lond.), 395: 604-608, 1998.[Medline]
  50. Roose J., Molenaar M., Peterson J., Hurenkamp J., Brantjes H., Moerer P., van de Wetering M., Destree O., Clevers H. The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature (Lond.), 395: 608-612, 1998.[Medline]
  51. Waltzer L., Bienz M. Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling. Nature (Lond.), 395: 521-525, 1998.[Medline]
  52. Zorn A. M., Barish G. D., Williams B. O., Lavender P., Klymkowsky M. W., Varmus H. E. Regulation of Wnt signaling by Sox proteins: XSox17 {alpha}/ß and XSox3 physically interact with ß-catenin. Mol. Cell, 4: 487-498, 1999.[Medline]
  53. Ishitani T., Tsuji J., Nagai S., Nishita M., Meneghini M., Barker N., Waterman M., Bowerman B., Clevers H., Shibuya H., Matsumoto K. The TAK1-NLK-MAPK-related pathway antagonizes signalling between ß-catenin and transcription factor TCF. Nature (Lond.), 399: 798-802, 1999.[Medline]
  54. Rocheleau C. E., Yasuda J., Shin T. H., Lin R., Sawa H., Okano H., Priess J. R., Davis R. J., Mello C. C. WRM-1 activates the LIT-1 protein kinase to transduce anterior/posterior polarity signals in C. elegans. Cell, 97: 717-726, 1999.[Medline]
  55. Valkovic T., Lucin K., Krstulja M., Dobi-Babic R., Jonjic N. Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol. Res. Pract., 194: 335-340, 1998.[Medline]
  56. Kleine-Lowinski K., Gillitzer R., Kuhne-Heid R., Rosl F. Monocyte-chemo-attractant-protein-1 (MCP-1)-gene expression in cervical intra-epithelial neoplasias and cervical carcinomas. Int. J. Cancer, 82: 6-11, 1999.[Medline]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
G. T. Bommer, C. Jager, E.-M. Durr, S. Baehs, S. T. Eichhorst, T. Brabletz, G. Hu, T. Frohlich, G. Arnold, D. C. Kress, et al.
DRO1, a Gene Down-regulated by Oncogenes, Mediates Growth Inhibition in Colon and Pancreatic Cancer Cells
J. Biol. Chem., March 4, 2005; 280(9): 7962 - 7975.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Fujita, Y. Furukawa, T. Tsunoda, T. Tanaka, M. Ogawa, and Y. Nakamura
Up-Regulation of the Ectodermal-Neural Cortex 1 (ENC1) Gene, a Downstream Target of the {beta}-Catenin/T-Cell Factor Complex, in Colorectal Carcinomas
Cancer Res., November 1, 2001; 61(21): 7722 - 7726.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujita, M.
Right arrow Articles by Nakamura, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujita, M.
Right arrow Articles by Nakamura, Y.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online